BYSI News and Press, BeyondSpring Inc. From 07/16/19

NEW YORK, July 16, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology cancer therapies, toda...

BeyondSpring (NASDAQ: BYSI ): Q1 GAAP EPS of -$0.32. More news on: BeyondSpring Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- New and Compelling Plinabulin Data Presented at Key Scientific Conferences - - To Submit New Drug Applications (NDAs) in China for Both Non-Small Cell Lung Cancer (NSCLC) and Chemotherapy-Induced Neutropenia (CIN) in Q4 2019 / Q1 2020 - - To Submit NDAs in the U.S. for Both NSCL...

NEW YORK, June 20, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that it will join the FTSE Russell 3000 ® Index at the conclusion of the 2019 Russell indexes annual ...

The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) was on the decline last week, dropping from 3,269.13 points on Monday (June 10) to 3,238.69 points as of 2:08 p.m. EDT on Friday (June 14). Last week, Provention Bio (NASDAQ: PRVB ) announced a public offering of its common stock on Monday...

NEW YORK, June 04, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that management will provide a corporate overview at the Jefferies 2019 Healthcare Conference in New...

NEW YORK, May 20, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company’s abstract on its lead asset, Plinabulin, has been accepted for poster prese...

NEW YORK, May 16, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that two of the Company’s abstracts on its lead asset, Plinabulin, have been accepted for pub...

BeyondSpring Inc. (BYSI) Q4 2018 Results Earnings Conference Call April 30, 2019, 08:00 AM ET Company Participants Stephen Kilmer - IR Lan Huang - Chairman and CEO Ramon Mohanlal - EVP of Research and Development and Chief Medical Officer Richard Daly - COO Edward Liu - CFO ...

NEW YORK, April 30, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2018 with the...